(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202409 | 202309 | % Var | 202409 | 202309 | % Var | 202403 | 202303 | % Var | |
| Sales | 30.28 | 34.94 | -13.34 | 56.81 | 75.56 | -24.81 | 144.72 | 131.29 | 10.23 |
| Other Income | 0.78 | 0.45 | 73.33 | 0.78 | 0.45 | 73.33 | 2.69 | 3.76 | -28.46 |
| PBIDT | 2.24 | 1.76 | 27.27 | 4.24 | 4.86 | -12.76 | 4.98 | 4.06 | 22.66 |
| Interest | 0.03 | 0.05 | -40.00 | 0.06 | 0.06 | 0.00 | 0.14 | 0.07 | 100.00 |
| PBDT | 2.21 | 1.71 | 29.24 | 4.18 | 4.80 | -12.92 | 4.84 | 3.99 | 21.30 |
| Depreciation | 0.41 | 0.55 | -25.45 | 0.82 | 1.07 | -23.36 | 2.09 | 2.80 | -25.36 |
| PBT | 1.80 | 1.16 | 55.17 | 3.36 | 3.73 | -9.92 | 2.75 | 1.19 | 131.09 |
| TAX | 0.85 | 0.00 | 0.00 | 0.85 | 0.00 | 0.00 | 0.72 | 0.40 | 80.00 |
| Deferred Tax | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.02 | 0.09 | -77.78 |
| PAT | 0.95 | 1.16 | -18.10 | 2.51 | 3.73 | -32.71 | 2.03 | 0.79 | 156.96 |
| Equity | 53.74 | 53.74 | 0.00 | 53.74 | 53.74 | 0.00 | 53.74 | 53.74 | 0.00 |
| PBIDTM(%) | 7.40 | 5.04 | 46.86 | 7.46 | 6.43 | 16.04 | 3.44 | 3.09 | 11.28 |
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1819.95 |
| Dr. Reddys Lab | 1278.10 |
| Cipla | 1328.95 |
| Zydus Lifesciences | 907.15 |
| Lupin | 2333.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: